Latest Conference Articles

Enhertu Fulfills ‘Big Unmet Need’ for Patients with HER2-Low Metastatic Breast Cancer

Enhertu Fulfills ‘Big Unmet Need’ for Patients with HER2-Low Metastatic Breast Cancer

June 7th 2022, 3:00pm

The findings of the study show that Enhertu should be a new standard of care for patients with HER2-low metastatic breast cancer, according to an expert at Memorial Sloan Kettering Cancer Center.

Addition of Tiragolumab to Tecentriq-Chemo Combo Fails to Boost Outcomes in Small Cell Lung Cancer

Addition of Tiragolumab to Tecentriq-Chemo Combo Fails to Boost Outcomes in Small Cell Lung Cancer

June 6th 2022, 9:00pm

Survival outcomes and side effect rates were similar in patients with extensive-stage small cell lung cancer who did and did not have tiragolumab added to their treatment regimen of Tecentriq and chemotherapy.

Keytruda-Cyramza Combo Bests Standard-of-Care Therapies in Previously Treated Non-Small Cell Lung Cancer

Keytruda-Cyramza Combo Bests Standard-of-Care Therapies in Previously Treated Non-Small Cell Lung Cancer

June 6th 2022, 7:00pm

Despite similar responses to treatment, patients with previously treated non-small cell lung cancer derived a better overall survival benefit from treatment with Keytruda combined with Cyramza than the usage of standard-of-care therapies.

Early Study Findings Show Novel Drug Elicits Promising Results in Metastatic Breast Cancers

Early Study Findings Show Novel Drug Elicits Promising Results in Metastatic Breast Cancers

June 6th 2022, 3:00pm

At a follow-up of more than two years, treatment with a novel drug produced meaningful results in a group of patients with HER3-expressing metastatic breast cancer or metastatic triple-negative breast cancer.

SOT101 With or Without Keytruda Shows Promise, Safety in Treating Advanced Solid Tumors

SOT101 With or Without Keytruda Shows Promise, Safety in Treating Advanced Solid Tumors

June 6th 2022, 1:00pm

ASCO Annual Meeting

The investigational agent SOT101 was safe and tolerable when given alone and in combination with Keytruda for patients with solid tumors.

Calquence-Based Regimens Continue to Elicit Better Results Than Gazyva Plus Chemotherapy in Untreated Chronic Lymphocytic Leukemia

Calquence-Based Regimens Continue to Elicit Better Results Than Gazyva Plus Chemotherapy in Untreated Chronic Lymphocytic Leukemia

June 5th 2022, 10:00pm

ASCO Annual Meeting

Long-term study results show that outcomes, such as survival and response rates, in patients who have received Calquence-containing treatment regimens continue to outpace outcomes in those who were given Gazyva and chemotherapy.

Trodelvy Reduces Risk of Disease Progression in Certain Patients With Metastatic Breast Cancer

Trodelvy Reduces Risk of Disease Progression in Certain Patients With Metastatic Breast Cancer

June 5th 2022, 5:15pm

Treatment with Trodelvy resulted in slight survival improvements, when compared with standard of care chemotherapy regimens, in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Adcetris Plus Chemo ‘Potentially Cured’ Some Patients With Hodgkin Lymphoma

Adcetris Plus Chemo ‘Potentially Cured’ Some Patients With Hodgkin Lymphoma

June 5th 2022, 1:00pm

ASCO Annual Meeting

Adcetris plus doxorubicin, vinblastine and dacarbazine is the first regimen to improve overall survival compared to the current standard of care for patients with advanced-stage classical Hodgkin lymphoma.

Tibsovo Plus Vidaza Is Beneficial for Patients With IDH1-Mutant Acute Myeloid Leukemia

Tibsovo Plus Vidaza Is Beneficial for Patients With IDH1-Mutant Acute Myeloid Leukemia

June 4th 2022, 11:50pm

ASCO Annual Meeting

Tibsovo plus Vidaza led to survival benefit for patients with IDH1-mutant acute myeloid leukemia, according to findings from the AGILE clinical trial.

Cabometyx Failed to Improve Survival in Advanced Bladder Cancer

Cabometyx Failed to Improve Survival in Advanced Bladder Cancer

June 4th 2022, 10:00pm

ASCO Annual Meeting

While Cabometyx had a favorable side effect profile, it did not lead to a significant survival advantage over placebo in a clinical trial.

New Drug May Mitigate Incidence, Severity of Chemotherapy-Related Oral Mucositis in Patients With Head and Neck Cancer

New Drug May Mitigate Incidence, Severity of Chemotherapy-Related Oral Mucositis in Patients With Head and Neck Cancer

June 4th 2022, 7:00pm

ASCO Annual Meeting

Avasopasem manganese is the first drug that has been shown to reduce the incidence and severity of chemotherapy-related oral mucositis in patients with head and neck cancer, research showed.

Treatment With Vonjo May Elicit Fewer Side Effects Than Other Available Therapies in Myelofibrosis, a Rare Type of Blood Cancer

Treatment With Vonjo May Elicit Fewer Side Effects Than Other Available Therapies in Myelofibrosis, a Rare Type of Blood Cancer

June 4th 2022, 3:00pm

Vonjo proved to have a similar, or superior, side effect profile compared with the best available therapy for patients with myelofibrosis, a form of blood cancer.

 Adagrasib Shows Promise in Difficult-to-Treat Lung Cancer Subset

Adagrasib Shows Promise in Difficult-to-Treat Lung Cancer Subset

June 4th 2022, 1:00pm

ASCO Annual Meeting

Adagrasib demonstrated an 80% disease control rate among patients with previously treated KRAS G12C–mutated non–small cell lung cancer.

Hispanic Children With Neuroblastoma Have Poorer Trial Outcomes: Describing Disparities Is ‘Simply Not Enough’

Hispanic Children With Neuroblastoma Have Poorer Trial Outcomes: Describing Disparities Is ‘Simply Not Enough’

June 1st 2022, 3:00pm

ASCO Annual Meeting

Research showed that Hispanic children with neuroblastoma who are participating on clinical trials tended to have worse survival outcomes than others.

Educated Patient® MPN Summit Disease Approaches Panel: May 7, 2022

Educated Patient® MPN Summit Disease Approaches Panel: May 7, 2022

May 24th 2022, 1:00pm

Educated Patient® MPN Summit: May 7, 2022

Watch Dr. Jamile Shammo and Dr. Srdan Vestovsek answer questions about disease approaches during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Novel Agents & Clinical Trials in Myelofibrosis Presentation: May 7, 2022

Educated Patient® MPN Summit Novel Agents & Clinical Trials in Myelofibrosis Presentation: May 7, 2022

May 23rd 2022, 1:00pm

Educated Patient® MPN Summit: May 7, 2022

Watch Dr. Srdan Vestovsek, from The University of Texas MD Anderson Cancer Center, discuss novel agents and clinical trials in myelofibrosis, during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Differentiating an Essential Thrombocythemia Diagnosis Presentation: May 7, 2022

Educated Patient® MPN Summit Differentiating an Essential Thrombocythemia Diagnosis Presentation: May 7, 2022

May 22nd 2022, 2:00pm

Watch Dr. Jamile Shammo, from Rush University Medical Center, discuss differentiating an essential thrombocythemia diagnosis, during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Focus on Clinical Trials Panel: May 7, 2022

Educated Patient® MPN Summit Focus on Clinical Trials Panel: May 7, 2022

May 21st 2022, 2:00pm

Educated Patient® MPN Summit: May 7, 2022

Watch Dr. Jamile Shammo, Dr. Angela Fleishman and Kapila Viges answer questions about clinical trials during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Clinical Trials Presentation: May 7, 2022

Educated Patient® MPN Summit Clinical Trials Presentation: May 7, 2022

May 20th 2022, 1:00pm

Educated Patient® MPN Summit: May 7, 2022

Watch Kapila Viges, from the MPN Research Foundation, discuss clinical trials, during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Novel Agents and Clinical Trials in Polycythemia Vera Presentation: May 7, 2022

Educated Patient® MPN Summit Novel Agents and Clinical Trials in Polycythemia Vera Presentation: May 7, 2022

May 19th 2022, 1:00pm

Educated Patient® MPN Summit: May 7, 2022

Watch Dr. Angela Fleishman, from the University of California Irvine, discuss novel agents and clinical trials in polycythemia vera, during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Diagnoses and Treatment Panel: May 7, 2022

Educated Patient® MPN Summit Diagnoses and Treatment Panel: May 7, 2022

May 18th 2022, 1:00pm

Educated Patient® MPN Summit: May 7, 2022

Watch Dr. Jamile Shammo, Dr. Aaron Gerds and Dr. Bart Scott, answer questions during the diagnoses and treatment panel during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Current Treatment Options Presentation: May 7, 2022

Educated Patient® MPN Summit Current Treatment Options Presentation: May 7, 2022

May 17th 2022, 1:00pm

Educated Patient® MPN Summit: May 7, 2022

Watch Dr. Bart Scott, from Fred Hutchinson Cancer Center, discuss current treatment options, during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Approach to Diagnosing & Assessing Symptoms Presentation: May 7, 2022

Educated Patient® MPN Summit Approach to Diagnosing & Assessing Symptoms Presentation: May 7, 2022

May 16th 2022, 1:00pm

Educated Patient® MPN Summit: May 7, 2022

Watch Dr. Aaron Gerds, from Cleveland Clinic Taussig Cancer Institute, discuss approaches to diagnosing and assessing symptoms, during the CURE Educated Patient MPN Summit.

Educated Patient® Kidney Cancer Summit Combination Therapy Panel: April 9, 2022

Educated Patient® Kidney Cancer Summit Combination Therapy Panel: April 9, 2022

May 1st 2022, 2:00pm

Educated Patient® Kidney Cancer Summit: April 9, 2022

Watch Dr. Thomas Hutson, Dr. Saby George, Dr. Jeff Yorio and Louise Gunter answer questions about combination therapy, during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit IO/TKI-Related Side Effects Presentation: April 9, 2022

Educated Patient® Kidney Cancer Summit IO/TKI-Related Side Effects Presentation: April 9, 2022

April 30th 2022, 2:00pm

Educated Patient® Kidney Cancer Summit: April 9, 2022

Watch Louise Gunter, from Texas Oncology, discuss IO/TKI-related side effects, during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit IO/TKI Therapies Presentation: April 9, 2022

Educated Patient® Kidney Cancer Summit IO/TKI Therapies Presentation: April 9, 2022

April 29th 2022, 1:00pm

Educated Patient® Kidney Cancer Summit: April 9, 2022

Watch Dr. Jeff Yorio, from Texas Oncology, discuss treatment with the combination of immunotherapy and tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit IO/IO Therapies Presentation: April 9, 2022

Educated Patient® Kidney Cancer Summit IO/IO Therapies Presentation: April 9, 2022

April 28th 2022, 3:43pm

Educated Patient® Kidney Cancer Summit: April 9, 2022

Watch Dr. Saby George, from Roswell Park Comprehensive Cancer Center, discuss treatment with the combination of immunotherapies, during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit Panel on Communicating With Providers About Immunotherapy/TKI Combo Treatment: April 9, 2022

Educated Patient® Kidney Cancer Summit Panel on Communicating With Providers About Immunotherapy/TKI Combo Treatment: April 9, 2022

April 27th 2022, 1:00pm

Educated Patient® Kidney Cancer Summit: April 9, 2022

Watch Dr. Thomas Hutson, Louise Gunter and Meryl Uranga discuss communicating with a care team about treatment with immunotherapy combined with tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit Panel on Side Effects from Immunotherapy/TKI Combo Treatment: April 9, 2022

Educated Patient® Kidney Cancer Summit Panel on Side Effects from Immunotherapy/TKI Combo Treatment: April 9, 2022

April 26th 2022, 1:00pm

Educated Patient® Kidney Cancer Summit: April 9, 2022

Watch Dr. Thomas Hutson, Louise Gunter and Meryl Uranga discuss side effects and dose reductions after treatment with immunotherapy combined with tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit Panel on Immunotherapy/TKI Combo Treatment: April 9, 2022

Educated Patient® Kidney Cancer Summit Panel on Immunotherapy/TKI Combo Treatment: April 9, 2022

April 25th 2022, 1:00pm

Educated Patient® Kidney Cancer Summit: April 9, 2022

Watch Dr. Thomas Hutson, Louise Gunter and Meryl Uranga discuss the treatment of combining immunotherapy with tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.